共 50 条
Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer
被引:3
|作者:
Astiazaran-Symonds, Esteban
[1
,2
,3
]
Graham, Cole
[1
]
Kim, Jung
[1
]
Tucker, Margaret A.
[1
]
Ingvar, Christian
[4
]
Helgadottir, Hildur
[5
,6
]
Pastorino, Lorenza
[7
,8
]
van Doorn, Remco
[9
]
Sampson, Joshua N.
[1
]
Zhu, Bin
[1
,10
]
Bruno, William
[7
,8
]
Queirolo, Paola
[11
]
Fornarini, Giuseppe
[12
]
Sciallero, Stefania
[12
]
Carter, Brian
[13
]
Hicks, Belynda
[1
,10
]
Hutchinson, Amy
[1
,10
]
Jones, Kristine
[1
,10
]
Stewart, Douglas R.
[1
]
Chanock, Stephen J.
[1
]
Freedman, Neal D.
[1
]
Landi, Maria Teresa
[1
]
Hoiom, Veronica
[5
,6
]
Puig, Susana
[14
,15
]
Gruis, Nelleke
[9
]
Yang, Xiaohong R.
[1
]
Ghiorzo, Paola
[7
,8
]
Goldstein, Alisa M.
[1
]
机构:
[1] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD USA
[2] Natl Human Genome Res Inst, NIH, Bethesda, MD USA
[3] Univ Arizona, Coll Med Tucson, Dept Med, Tucson, AZ USA
[4] Univ Lund Hosp, Dept Surg, Lund, Sweden
[5] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[6] Karolinska Univ Hosp, Stockholm, Sweden
[7] IRCCS Osped Policlin San Martino, Genet Rare Canc, Genoa, Italy
[8] Univ Genoa, Dept Internal Med & Med Specialties, Genoa, Italy
[9] Leiden Univ, Dept Dermatol, Med Ctr, Leiden, Netherlands
[10] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Canc Genom Res Lab, Frederick, MD USA
[11] IEO European Inst Oncol, Melanoma Sarcoma & Rare Tumors, Milan, Italy
[12] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy
[13] Amer Canc Soc, Atlanta, GA USA
[14] Univ Barcelona, Hosp Clin Barcelona, Melanoma Unit, IDIBAPS, Barcelona, Spain
[15] CIBERER, Barcelona, Spain
基金:
美国国家卫生研究院;
欧洲研究理事会;
英国医学研究理事会;
关键词:
MELANOMA-PRONE FAMILIES;
FOUNDER MUTATION;
HIGH-RISK;
PREDISPOSITION;
PREVALENCE;
BREAST;
COHORT;
DESIGN;
COMMON;
LUNG;
D O I:
10.1200/PO.22.00145
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
PURPOSE Pancreatic ductal adenocarcinoma (PDAC) is a component of familial melanoma due to germline pathogenic variants (GPVs) in CDKN2A. However, it is unclear what role this gene or other genes play in its etiology. MATERIALS AND METHODS We analyzed 189 cancer predisposition genes using parametric rare-variant association (RVA) tests and nonparametric permutation tests to identify gene-level associations in PDAC for patients with (CDKN2A+) and without (CDKN2A-) GPV. Exome sequencing was performed on 84 patients with PDAC, 47 CDKN2A+ and 37 CDKN2A-. After variant filtering, various RVA tests and permutation tests were run separately by CDKN2A status. Genes with the strongest nominal associations were evaluated in patients with PDAC from The Cancer Genome Atlas and the UK Biobank (UKB). A secondary analysis including only GPV from UKB was also performed. RESULTS In RVA tests, ERCC4 and RET showed the most compelling evidence as plausible PDAC candidate genes for CDKN2A+ patients. In contrast, the findings in CDKN2A- patients provided evidence for HMBS, EPCAM, and MRE11 as potential new candidate genes and confirmed ATM, BRCA2, and PALB2 as PDAC genes, consistent with findings in The Cancer Genome Atlas and the UKB. As expected, CDKN2A- patients were more likely to harbor GPVs from the 189 genes investigated. When including only GPVs from UKB, significant associations with PDAC were seen for ATM, BRCA2, and CDKN2A. CONCLUSION These results suggest that variants in other genes likely play a role in PDAC in all patients and that PDAC in CDKN2A+ patients has a distinct etiology from PDAC in CDKN2A- patients.
引用
收藏
页数:9
相关论文